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INTRODUCTION
Allogeneic BMT is being used to treat leukemia that is
refractory to conventional therapy. Problems associated with
this treatment still remain, however, including GVHD and
leukemia relapse. GVHD can be avoided if donor T cells in
the marrow graft are removed, but elimination of the T cells
increases the risk for leukemia relapse [1]. The antitumor
benefit provided by the donor T cells is known as the graft-
vs.-leukemia (GVL) effect. The ongoing challenge for
researchers and clinicians is to find ways of harnessing the
beneficial GVL effect of allogeneic BMT while avoiding
life-threatening GVHD.
If a leukemia patient relapses after an allogeneic BMT,
treatment options are limited and include additional chemo-
therapy, a second marrow transplant, or cytokine therapy
[2]. Unfortunately, these treatments have not been highly
successful and are often associated with unacceptable toxici-
ties. Cellular immunotherapy, given as infusions of lympho-
cytes from the original BM donor, is currently being used
worldwide to successfully treat posttransplant leukemia
relapse. This treatment, often referred to as delayed or
donor lymphocyte infusion (DLI), has been particularly suc-
cessful for treating CML relapse. Success rates as high as
80% have been reported [3,4]. DLI has been less successful
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ABSTRACT
Infusions of donor leukocytes have been given to allogeneic bone marrow recipients after transplant to treat
leukemia relapse. Treatment with these delayed infusions of donor cells has been called delayed or donor leuko-
cyte infusion (DLI). While graft-vs.-host disease (GVHD) has typically been less severe than expected after DLI, it
still remains a significant risk factor. Recently, we used a full major histocompatibility complex (MHC)-mis-
matched model (C57BL/6 into AKR) to determine how increased immunogenetic disparity affects GVH and graft-
vs.-leukemia (GVL) reactions after DLI. In contrast to an MHC-matched model (B10.BR into AKR), GVHD was
still observed when MHC-mismatched donor T cells were infused 3 weeks posttransplant. Limiting dilution analy-
sis was used to determine the frequency of alloreactive cytotoxic T lymphocytes (CTL) and interleukin (IL)-
2–secreting T helper cells in the spleens of MHC-mismatched recipients 7 days after DLI treatment. GVHD cor-
related with elevated frequencies of alloreactive T-helper cells. One strategy for reducing the severity of GVHD
after DLI is the selective administration of CD4 or CD8 T-subsets. Delayed infusion of purified T-subsets 3 weeks
posttransplant resulted in significantly less GVHD than infusion of a mixture of the two subsets. No GVH-associ-
ated mortality was observed after DLI with purified donor CD4+ T cells. In GVL studies, MHC-mismatched CD8+
T cells were the most potent antitumor effectors against an acute T cell leukemia. The GVL effect of MHC-mis-
matched T-subsets was compared with that of MHC-matched subsets. When naive MHC-matched cells were
given as DLI, depletion of either T-subset eliminated the GVL effect. CD8+ T cells from MHC-matched donors
primed against host alloantigens, however, mediated a CD4 (T-helper)–independent GVL reaction. Together,
these results suggest that administration of T-subsets can significantly reduce GVHD after DLI without loss of
the beneficial GVL effect.
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for treating acute leukemia; complete remissions have been
observed in only 15–18% of treated patients [4]. The sur-
prising aspect of DLI therapy is that relatively large num-
bers of donor T cells can be given with less GVHD than
anticipated if similar numbers of T cells were given at the
time of BMT. In fact, some patients given DLI have been
successfully treated without developing GVHD [3–6]. For
most patients treated with DLI, however, GVHD remains a
life-threatening problem occurring in ~60% of patients [4].
A major issue for DLI is whether the incidence of GVHD
can be further decreased without affecting the beneficial
GVL effect. To address this issue, the GVL effector cells
need to be defined and characterized.
Our laboratory has developed murine models to investi-
gate important clinical issues regarding DLI therapy. We
previously demonstrated that DLI could be given to MHC-
matched murine recipients to provide a GVL effect without
GVHD if the donor cell administration was delayed until at
least 3 weeks posttransplant [7,8]. In this report, we investi-
gate how increased immunogenetic disparity in an MHC-
mismatched combination of murine allogeneic BMT affects
GVHD after DLI. In addition, the effect of T-subset deple-
tion on GVH and GVL reactivity after DLI was examined
in MHC-mismatched and -matched models.
MATERIALS AND METHODS
Mice
AKR (H-2k, Thy1.1), B10.BR (H-2k, Thy1.2), and
C57BL/6 (H-2b, Thy1.2) mice were obtained from Jackson
Laboratory (Bar Harbor, ME) and cared for in the Medical
College of Wisconsin Animal Resource Center (Milwaukee,
WI), which is accredited by the American Association for
the Accreditation of Laboratory Animal Care (AALAC).
Bone marrow transplants
AKR hosts (6–8 weeks old) were preconditioned for
BMT with a lethal dose of 1100 cGy total body irradiation
(TBI) from a cesium source (irradiator). BM was obtained
by flushing the femurs and tibias of normal, healthy B10.BR
or C57BL/6 donors. Two to four hours after irradiation, the
hosts were given a single i.v. injection of 0.75–1.53107
donor BM cells with or without admixed splenocytes or
purified splenic T cells. In selected experiments, the donor
BM was depleted of T cells ex vivo or in vivo. For ex vivo
depletion, the BM cells were treated with bioreactor-derived
anti-Thy1.2 monoclonal antibody (clone 30-H12; ATCC,
Rockville, MD) and complement. For in vivo depletion, the
marrow donors were injected i.p. with 75 µg anti-Thy1.2
monoclonal antibody 5 and 2 days before BM harvest. T cell
depletion was confirmed by flow cytometric analysis.
For DLI experiments, donor spleen cells or purified
splenic T cells were given i.v. at various times posttrans-
plant. For T cell purification, a magnetic-activated cell sepa-
ration (MACS) system (Miltenyi Biotec, Sunnyvale, CA) was
used. T cells were positively selected in magnetic columns
after incubation with anti-CD4, anti-CD8, or anti-Thy1.2
conjugated microbeads. The MACS microbeads are very
small (~50 nm in diameter) and have not affected cell func-
tion in our studies. For depletion of CD4 or CD8 T-subsets,
spleen cells were treated with anti-L3T4 (clone GK1.5;
ATCC) or anti-Lyt2.2 (clone 2.43; ATCC) and comple-
ment, respectively.
For preimmunization of donors against AKR alloanti-
gens, B10.BR mice were injected i.p. twice a week with 107
normal AKR splenocytes. One week after the final injection,
the donors were killed and the spleens harvested for use in
DLI experiments.
Leukemia
A spontaneously arising acute T cell leukemia of AKR
origin was isolated from the spleen of a male AKR mouse
and passaged in vivo. After passage, the leukemia (designat-
ed M2) was reisolated and frozen. Vials of the frozen stock
were thawed for leukemia-challenge experiments. This
strategy was used to minimize experimental variability. The
leukemia cells are CD4+, Thy1.1+, MHC class I+, MHC-
class II–, and variable for CD8 expression. For tumor chal-
lenge experiments, mice were injected i.v. with indicated
numbers of leukemia cells.
Culture medium
The culture medium consisted of Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco, Grand Island, NY) sup-
plemented with 10% heat-inactivated fetal bovine serum,
5310–5 M 2-mercaptoethanol, antibiotics, and additional
amino acids [9].
Limiting dilution analysis (LDA) assays
LDA assays were used to determine T-helper cell and
cytolytic T lymphocyte (CTL) precursor frequencies as
previously described [8]. The spleen cells from three indi-
vidual BMT chimeras were isolated and pooled. Responder
T cells were enriched by positive selection using MACS
with anti-Thy1.2 conjugated microbeads. To assess allore-
active T-helper cell frequencies, Thy1.2-enriched respon-
der cells were cocultured at eight different concentrations
in 16 replicate U-bottomed microwells with 2.53104 irradi-
ated (3000 cGy) AKR peritoneal exudate cells (200 µL/well
total volume). After 4 days of culture in a 37°C, 10% CO2
incubator, 150 µL of culture supernatant was removed from
each well and transferred to a new microwell plate contain-
ing 4000 interleukin (IL)-2–dependent SAC 9.12 [10] indi-
cator cells and 1 µCi [3H]thymidine. The plates were cul-
tured an additional 18–24 hours, and thymidine uptake was
assessed. Spontaneous thymidine uptake was determined
from the supernatants of 48 wells that had contained stimu-
lator cells only.
To assess CTL frequencies, various numbers of Thy1.2-
enriched responder cells were cocultured with 53105 irradi-
ated (3000 cGy) AKR spleen cell stimulators (16 wells per
responder cell concentration). Concanavalin A (con A)–stim-
ulated rat spleen cell conditioned medium was added to the
wells at a concentration of 40% (vol/vol). The plates were
cultured for 8 days. On day 8, the contents of each well was
mixed, and 150 µL of cell suspension was transferred to V-
bottomed microtiter plates with 50 µL [51Cr]-labeled AKR
con A–stimulated lymphoblast targets (5000 per well). 51Cr
release was assessed after a 3.5-hour incubation. Spontaneous
and maximum 51Cr release values were determined from 16
wells containing target cells plus stimulators only or deter-
gent (2.5% 73 detergent; Flow Laboratories), respectively.
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Individual wells in the T-helper cell and CTL assays
were scored as positive when experimental values (cpm
[3H]thymidine uptake or percent specific 51Cr release)
exceeded the spontaneous control values by at least 3SD.
The frequencies of alloreactive T-helper cells and CTL were
calculated by x2 minimization as described by Taswell [11].
Statistics
Survival curves were compared using the log-rank test.
RESULTS
DLI with MHC-mismatched donor cells can be given
without causing GVHD at 4 weeks posttransplant
We previously showed in MHC-matched and -haplomis-
matched models of allogeneic BMT that donor lymphocytes
can be given to recipients 3 weeks after transplant without
any clinical evidence of GVHD [7,8]. In this study, our trans-
plant model was adapted to study the impact of full MHC
disparity. AKR recipients were given a lethal dose of TBI and
injected i.v. with 107 MHC-mismatched C57BL/6 BM cells
with or without different doses of spleen cells (0.5–3.03107)
as a source of donor T cells. Groups of mice given BM only
received DLI 3 weeks after marrow transplant. The experi-
ments were staggered so that the groups given DLI were
transplanted 3 weeks before those groups given spleen cells
on the day of marrow transplant. In this way, the spleen cells
given to all groups were from the same pool of cells.
As shown in Fig. 1A, all groups of mice given spleen
cells on the day of transplant died. They rapidly developed
clinical signs of acute GVHD (diarrhea, body weight loss,
and ruffled fur). When the infusion of donor spleen cells
was delayed until 21 days posttransplant (Fig. 1B), signifi-
cant GVH-related mortality still occurred at all doses of
splenocytes administered. There was no statistically signifi-
cant difference in mortality between the groups that
received 1.0, 2.0, or 3.03107 splenocytes (~0.4–1.23109/kg
body weight); however, there was significantly less mortality
(p = 0.02) in the group given 0.53107 splenocytes
(0.23109/kg) vs. the group given 3.03107 splenocytes
(1.23109/kg) (Fig. 1B). While significant GVHD was
observed after DLI on day 21 post-BMT, all groups given
DLI (with the exception of the group given 2.03107 cells)
had significantly better survival rates than their respective
counterparts given donor spleen cells on the day of trans-
plant (p < 0.008). These data indicate that GVHD occurred
after DLI at 21 days posttransplant in this MHC-mis-
matched model, but that GVH-associated mortality was less
than that observed when comparable numbers of donor cells
were given at the time of marrow transplantation.
The next series of experiments was designed to investigate
whether GVHD could be avoided if DLI was delayed longer
than 21 days posttransplant. When infusion of 33107 donor
spleen cells (~1.23109/kg) was delayed until 28 days posttrans-
plant, all recipients survived to 90 days post-BMT (Fig. 2A).
These animals exhibited little or no body weight loss after
DLI (Fig. 2B), reflecting the absence of clinically evident
GVHD. Survival and clinical appearance were identical to that
of the controls given non–T-depleted BM only. In contrast,
50% of the mice given DLI 1 week earlier (day 21) died of
GVHD-related complications by 90 days posttransplant (Fig.
2A). The presence of GVHD in these animals was reflected by
the 15–30% body weight loss after DLI (Fig. 2B).
We previously reported a correlation between low fre-
quency of alloreactive T-helper cells and absence of GVHD
[8]. In the current studies, T cells were isolated from the
spleens of MHC-mismatched chimeras and tested in LDA
assays to assess alloreactive T-helper cell and CTL frequen-
cies. As shown in Table 1, three groups of AKR recipients
were transplanted: 1) a GVH-negative control group given
C57BL/6 non–T-depleted BM only; 2) an experimental
group given C57BL/6 non–T-depleted BM followed by
DLI with 33107 donor spleen cells 21 days post-BMT; and
3) a GVH-positive control group given 33107 donor spleen
cells at the time of BMT. Mice given donor spleen cells
were killed 7 days after administration (i.e., either 28 or 7
days post-BMT), and the mice given BM only were killed
Figure 1. Lethal GVHD was not avoided when DLI was adminis-
tered to MHC-mismatched chimeras 21 days posttransplant
AKR recipients, preconditioned with lethal TBI, were injected i.v. with 107
non–T-depleted C57BL/6 BM cells. Doses of 0.5, 1, 2, or 33107 donor spleen
cells (~0.2 to 1.23109/kg) were coadministered with the BM (A; n=8
mice/dose) or given as a single i.v. injection 21 days after BMT ( B; n=8
mice/dose). The survival data were derived from the combination of two inde-
pendent experiments. Day 0 represents the day donor spleen cells were given
(either the day of BMT or 21 days post-BMT). None of the survival curves in
A were statistically different (p > 0.05).
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28 days post-BMT. Splenic T cells were isolated and tested
in LDA assays. The frequencies of alloreactive CTL in the
spleen were significantly different (nonoverlapping 95%
confidence intervals) between the three groups of chimeras,
the GVH-positive controls having the highest frequency
and the GVH-negative controls the lowest frequency (Table
1). The frequency of alloreactive T-helper cells between the
GVH-positive control group and the DLI experimental
group were not significantly different; however, both groups
had significantly higher T-helper frequencies than the
GVH-negative control group. Since the experimental mice
given DLI at 21 days post-BMT developed GVHD (Figs. 1
and 2), these results suggest a correlation between alloreac-
tive T-helper cell frequencies and the intensity of GVHD.
CD4+ or CD8+ T-subsets given 21 days posttransplant 
do not cause GVHD
Purified CD4+ and CD8+ T cells were used to determine
whether infusion of T-subsets could reduce the severity of
GVHD after DLI at 21 days in MHC-mismatched recipi-
ents. AKR hosts were transplanted with C57BL/6 BM alone
or admixed with purified T cells or T cell subsets. Trans-
plants were staggered so that all groups received donor
T cells on the same day from the same pool of cells. The
T cell suspensions were analyzed by flow cytometry before
infusion, so that the numbers of T-subset cells administered
(33106 for CD4+ and 23106 for CD8+) could be adjusted to
correspond with their respective numbers within the unsep-
arated T cell–enriched pool. The enriched T cells were
>90% pure, and the subset-enriched cells contained ≤1%
contaminating cells of the opposite subset. As shown in Fig.
3, purified donor T cells and both T-subsets given on the
day of BMT induced lethal GVHD. When the infusion of
T cells was delayed until 21 days post-BMT, mixed T cells
induced significantly less GVH-related mortality (p = 0.038)
than when given at the time of transplant (25 vs 0% sur-
vival), but GVHD was still severe as reflected by body
weight loss after infusion (Fig. 3B). DLI with T-subsets
resulted in significantly less GVH-related mortality com-
pared with DLI with mixed T cells (p < 0.047) (Fig. 3A).
Mice given DLI with CD4+ donor T cells had no deaths,
regained body weight after a modest initial loss of 10% (Fig.
3B), and exhibited a healthy clinical appearance. Although
30% of the mice given DLI with CD8+ donor T cells died
after infusion, the survivors regained body weight after an
initial loss and appeared generally healthy thereafter.
Figure 2. GVHD was avoided in MHC-mismatched chimeras if DLI administration was delayed until 28 days posttransplant
Irradiated AKR recipients were given 107 non–T-depleted C57BL/6 BM cells. The recipients were then randomized to receive no further treatment (BM only) or
DLI with 33107 C57BL/6 donor spleen cells at 21 (21d) or 28 (28d) days post-BMT. The curves show the combined posttransplant survival data of two experi-
ments (A) and the percent body weight loss or gain of recipients from one representative experiment starting at 21 days post-BMT (B). 
A B
Table 1. LDA assays to estimate the frequency of alloreactive CTL and IL-2-secreting T helper cells in the spleens of C57BL/6-AKR into chimeras 7 days post-T cells
CTL frequencies T-helper frequencies
Spleen cell Day Day CTL/106 Fold increase TH/10
6 Fold Increase
source postinfusion post-BMT cells over BM alone cells over BM alone
BM alone — 28 <20 656
BMS-30 (21d) 7 28 314 >16 1493* 2
BMS-30 (0d) 7 7 6,667 >333 1938* 3
Day postinfusion or post-BMT indicates the time when recipients were killed for LDA analysis. BM alone, C57BL/6 BM cells only; BMS-30 (21d), C57BL/6
BM cells followed 21 days later by 33107 C57BL/6 spleen cells; BMS-30 (0d), C57BL/6 BM cells admixed with 33107 C57BL/6 spleen cells.
*Overlapping 95% confidence intervals.
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Some survivors from the experiment shown in Fig. 3A
were killed 74 days after DLI to examine spleen size and
B cell content (Table 2). Splenic atrophy [12] and low B cell
content [13] are long-term sequelae of GVH reactivity. Two
survivors given CD8+ T cells on the day of marrow trans-
plant had small spleens (mean 1.33106 cells) and low B cell
content (mean 9.6%). Similarly, one survivor given DLI with
mixed donor T cells had a small spleen and relatively low B
cell content. In contrast, the mice given DLI with CD4+ or
CD8+ T cells had larger spleen sizes (mean 43.13106 and
50.83106 cells, respectively) and higher B cell content (mean
63.8 and 65.0%). Together, these results demonstrated that
DLI at 21 days with donor CD4+ or CD8+ T cells signifi-
cantly reduced the severity of GVHD and improved immune
recovery compared with DLI with unseparated T cells.
CD8+ donor T cells are the principal effector cells 
in the GVL response induced by DLI
MHC antigens are potent tumor rejection antigens,
whereas non-MHC encoded (minor) histocompatibility
antigens are less potent and often require presensitization or
priming of the donor to elicit a strong antitumor effect [14].
In the final series of experiments reported here, we exam-
ined the GVH reactivity of T-subsets from naive MHC-
mismatched, naive MHC-matched, and primed MHC-
matched donors.
Figure 3. DLI with purified T cells resulted in significantly less severe GVHD
Irradiated AKR recipients were given 107 MHC-mismatched non–T-depleted C57BL/6 BM cells. The recipients were then randomized to receive 53106 purified
donor T cells, 33106 purified donor CD4+ cells, or 23106 purified donor CD8+ T cells on the day of BMT (s, h, n) or 21 days posttransplant (d, j, m). The
curves show the combined survival data of two experiments (A) and the percent body weight loss or gain of recipients in one representative experiment (B; n=4–6
mice/group).
A
B
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First, CD4+ and CD8+ T cells were purified from the
spleens of naive C57BL/6 donors and given as DLI to
MHC-mismatched AKR hosts. The host mice, previously
transplanted with T cell–depleted C57BL/6 BM, were ran-
domized to be given 1) no DLI (BM only); 2) DLI at 28
days post-BMT with a mixture of 33106 purified CD4+ and
33106 purified CD8+ T cells; 3) DLI with 33106 purified
CD4+ T cells alone; or 4) DLI with 33106 purified CD8+ T
cells alone. DLI was given 28 days posttransplant to avoid
the GVHD observed when T cells were given at an earlier
time (Fig. 2). Mice within each experimental group were
randomized to be challenged with 100 (Fig. 4A), 1000 (Fig.
4B) or 10,000 (Fig. 4C) AKR-M2 leukemia cells on day 35
post-BMT (7 days post-DLI). When challenged with a rela-
tively low dose of 100 leukemia cells, all groups given DLI
had a significant GVL response as indicated by increased
survival over the control group given no DLI (BM only)
(Fig. 4A). The mice given CD8+ cells had a higher survival
rate than mice given CD4+ cells (56 vs. 27%), but the differ-
Table 2. Spleen sizes and splenic B cell content in long-term survivors of DLI
with T-subsets
Spleen size Percent splenic 
Group* Day of infusion† n (3106) B cells
CD8+ 0 2 1.3 ± 0.34 9.6 ± 8.1
Mixed 21 1 0.5 24.0
CD4+ 21 6 43.1 ± 22.6 63.8 ± 8.5
CD8+ 21 4 50.8 ± 4.0 65.0 ± 7.3
Viable splenic cell number was determined by visual counting and percent
splenic B cells by flow cytometry. Data are averages ± SD.
*Survivors from the experiments shown in Fig. 3 were killed 74 days after
T cell infusion.
†Post-BMT.
Figure 4. CD8+ T cells are the predominant GVL effector population in MHC-mismatched chimeras given DLI
Irradiated AKR recipients ere transplanted with 107 T-depleted C57BL/6 BM cells. Recipients were then randomized to receive no further treatment (BM only)
or DLI 28 days posttransplant with 33106 CD4+ donor T cells, 33106 CD8+ cells, or a mixture of 33106 CD4+ and 33106 CD8+ cells. One week later, (35
days post-BMT), the mice were challenged with 100 (A), 1000 (B), or 10,000 (C) AKR-M2 leukemia cells. The survival curves in each figure were derived from
the combined results of three experiments.
A
CB
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ence was not statistically significant. Survival in the CD8
DLI group was not significantly different from survival in
the group given the mixture of both T subsets (56 vs. 69%).
After challenge with the intermediate (1000) and high
(10,000) doses of leukemia cells, only the mice given CD8+
cells or the CD4/CD8 mixture showed a GVL effect as
manifested by increased survival rates over the BM-only
controls. At these higher doses of leukemia, mice given DLI
with CD4+ cells survived significantly longer than the mice
given BM only, but median survival time was only increased
by 3–4 days, and all eventually died.
To document whether mice in these experiments were
dying of tumor progression or GVHD, they were autopsied
for the presence of splenomegaly, an indicator of tumor pro-
gression in this experimental system, or splenic and thymic
atrophy, which is suggestive of GVHD. All of the BM-only
control mice were found to have splenomegaly at the time
of death, indicating that they died of tumor progression
(data not shown). In the groups of mice given DLI with the
mixture of both T cell subsets, only two of the 10 deaths
appeared to be due to leukemia progression, while six of the
remaining eight mice had splenic and thymic atrophy. These
results suggest that the majority of deaths in these experi-
mental groups were due to GVHD rather than leukemia. In
contrast, the majority of mice in the groups given DLI with
CD4+ or CD8+ T cells appeared to die of leukemia progres-
sion. Only two of 25 deaths in CD4+ DLI groups and two of
28 deaths in the CD8+ DLI groups appeared be from
GVHD as indicated by splenic and thymic atrophy. Taken
together, these observations suggest that the majority of the
deaths in these experiments, with the exception of the mice
given DLI with the mixture of both T subsets, appeared to
be due to leukemia progression and not GVHD.
Data from the experiments in Fig. 4 were used to quan-
tify the GVL effect in each group of mice. The dose of
leukemia needed to kill 50% of mice (LD50) was calculated
from regression curves generated by plotting log leukemia
dose vs. percent death (Table 3). The LD50 values for the
groups given no DLI (none) or DLI with purified CD4+
cells were too low to be quantified (LD50 < 100 leukemia
cells). DLI with CD8+ cells had a quantifiably greater GVL
effect (LD50 = 384 leukemia cells) than DLI with CD4
+ cells
or BM only, but the LD50 was 20-fold higher with mixed
CD4/CD8 T cells (LD50 = 7775 leukemia cells), indicating a
synergistic (helper) effect when CD4+ cells were added to
the CD8+ effector cells.
Additional groups of AKR mice were transplanted with
T-depleted MHC-matched B10.BR BM and randomized to
receive DLI at 21 days post-BMT using 1) B10.BR spleen
cells, 2) spleen cells depleted of CD4+ T cells, or 3) spleen
cells depleted of CD8+ T cells. All mice were challenged
with a lethal dose of 100 AKR-M2 leukemia cells 7 days
after DLI (28 days post-BMT) to assess GVL reactivity.
Normal nontransplanted AKR mice were injected as
leukemia controls. Mice given DLI with nondepleted donor
spleen cells exhibited a strong GVL effect (100% survival;
Fig. 5). These mice were followed as long as 139 days
postchallenge and were without clinically evident GVHD
(data not shown). Depletion of either CD4+ or CD8+ naive
T cells significantly compromised the GVL effect (Fig. 5).
Survival rates for these mice (0% for CD4-depleted and
17% for CD8-depleted) were not significantly higher than
for the nontransplanted AKR leukemia control group.
Spleen cells from B10.BR donor mice preimmunized
against AKR alloantigens were tested in DLI experiments to
determine if primed T cells induced a stronger GVL effect.
AKR mice that had been previously transplanted with
T cell–depleted B10.BR BM were infused 21 days post-
BMT with primed anti-host–reactive donor spleen cells (see
MATERIALS AND METHODS for immunization protocol) or
primed spleen cells depleted of CD4+ or CD8+ T-subsets.
One week later, the mice were challenged with 1000 AKR-
M2 leukemia cells. DLI with primed unseparated donor
splenocytes elicited an effective GVL response (Fig. 6), and
the mice did not develop clinically evident GVHD. In con-
trast to the results with naive donor cells (Fig. 5), the mice
given DLI with primed CD4-depleted (CD8+) donor spleen
cells had a significant GVL response (Fig. 6). The survival
rate for this group (75%) was not statistically different from
Table 3. Quantitative measure of the GVL effect in MHC-mismatched
chimeras given DLI with purified T cells
DLI* LD50 dose r
2
None <100
CD4+ <100
CD8+ 384 0.985
CD4+ + CD8+ 7775 0.916
For each group, a regression line was generated by plotting log leukemia dose
(100, 1000, and 10,000 cells) vs. percent death. The dose of leukemia needed
to kill 50% of mice (LD50) was determined from the regression line.
*Groups of mice from the experiments in Fig. 4.
Figure 5. DLI with donor cells depleted of CD4+ or CD8+ T cells
significantly compromised GVL reactivity in MHC-matched recipi-
ents
Irradiated AKR recipients were given 107 T-depleted B10.BR BM cells. The
recipients were then given DLI at 21 days posttransplant with 33107
B10.BR spleen cells that were untreated, CD4-depleted, or CD8-depleted.
One week later (28 days post-BMT), the mice were challenged with a lethal
i.v. dose of 100 AKR-M2 leukemia cells. A group of normal, nontransplanted
AKR mice were injected with the leukemia as a control. The survival curves
were derived from the combined results of two experiments.
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that of mice given nondepleted primed splenocytes (92%).
CD8 depletion of primed donor splenocytes (CD4+) signifi-
cantly reduced the GVL effect of DLI compared with those
given nondepleted splenocytes or CD4-depleted splenocytes
(p < 0.005) (18% survival); however, the GVL effect was not
completely lost. The majority of animals given DLI with T-
subset–depleted splenocytes that died after leukemia chal-
lenge were found to have splenomegaly, which is indicative
of leukemia progression. Overt clinical signs of GVHD
(diarrhea, wasting, and ruffled fur) were not observed in
mice given DLI with T-subset–depleted primed donor cells.
DISCUSSION
In the current report, we investigated the consequences
of increased immunogenetic disparity after DLI in a mouse
strain combination with complete MHC mismatch. We had
previously shown that DLI could be administered to murine
MHC-matched and -haplomismatched allogeneic recipients
without GVHD if infusion of the donor cells was delayed
until 21 days posttransplant [7,8]. In contrast to our previ-
ous data, GVHD occurred in an MHC-mismatched combi-
nation when DLI was given 21 days posttransplant (Figs. 1
and 2). This confirms the work of Blazar et al. [15], who
reported that GVHD developed after DLI with MHC-mis-
matched murine donor cells at 21 days posttransplant. We
extend their observation by showing that GVHD was avoid-
ed if DLI administration was delayed an additional week
(day 28 post-BMT) (Fig. 2), indicating that a longer time
interval between BMT and DLI was required to avoid
GVHD in full MHC-mismatched recipients. It is unknown
why this additional week is required. We have evidence,
however, that de novo generated thymus-derived cells of
donor origin play an important role in the suppression of
GVHD after DLI (B.D.J., unpublished observations), and
interestingly, preliminary data suggests that the kinetics of
“suppressor” cell development is delayed in the MHC-mis-
matched model compared with the MHC-matched model.
This delayed development of suppressor cells may explain
the additional week required to avoid GVHD in the MHC-
mismatched model. Increased immunogenetic disparity may
also be partly responsible for the increased time interval, but
we have no evidence to support this possibility.
We previously reported a correlation between low
alloreactive T-helper frequencies and absence of GVHD
after DLI in an MHC-matched model of DLI [8]. In the
present study, donor antihost T-helper cell frequencies in
day-21 recipients of MHC-mismatched DLI were compara-
ble to those of the GVHD controls (Table 1), lending fur-
ther support to the correlation between T-helper frequency
and GVHD. In agreement with our mouse data, Bunjes et
al. [16] found an association between the presence of allore-
active T-helper cells and GVHD in patients after DLI. In
contrast to the T-helper frequency data, CTL frequencies in
the spleens of day-21 DLI recipients were significantly
lower than those of the GVHD controls (Table 1). We do
not know the significance of this finding. However, since
GVHD is less severe in recipients of day 21 DLI than in
recipients of spleen cells on the day of transplant (Fig. 1, B
vs. A), we speculate that the lower CTL frequencies may be
a reflection of less severe GVHD in these mice. Perhaps
alloreactive T-helper cells in the DLI chimeras provide less
efficient “help” than those in the GVHD controls, thereby
resulting in the lower CTL frequencies found in the spleens
of DLI recipients. Decreased T-helper efficiency in the
DLI-treated mice might be due to lower cytokine produc-
tion by these helper cells. This possibility will be pursued in
future studies.
Although the severity of GVHD after DLI is less than
expected considering the high numbers of donor T cells
administered, GVHD can still be a significant clinical prob-
lem [3,4]. A number of approaches are being used in
attempts to reduce the incidence and severity of GVHD
after DLI, including suicide gene insertion [17,18], adminis-
tration of lower or escalating numbers of donor cells
[19,20], and selective depletion of T cell subsets [5]. Giralt
et al. [5] reported that only three of 10 patients given CD8-
depleted DLI for treatment of relapsed CML developed
GVHD, suggesting that the incidence of GVHD can be
lowered using this approach. In agreement with this clinical
observation, DLI with purified CD4+ or CD8+ T cells in our
mouse studies significantly reduced the severity of GVHD
in MHC-mismatched recipients (Fig. 3 and Table 2).
The effector cells responsible for the GVL effect of
DLI are unknown, but T cells and natural killer (NK) cells
are considered likely candidates. For CML, CD4+ T cells
have been implicated as effectors in the GVL response
[5,21,22]. This finding may be partly due to the fact that
CML cells express MHC class II molecules [23], which
could allow for the direct recognition of tumor cells by
CD4+ T cells. T cells were required for the GVL effect in
our murine models of DLI (Figs. 4–6). Furthermore, in
both the MHC-matched and -mismatched DLI models,
CD8+ cells were critical for the GVL response against the
Figure 6. CD8+ (CD4-depleted) T cells from primed donors medi-
ate a GVL effect in MHC-matched chimeras given DLI
Iradiated AKR recipients were given 107 T-depleted B10.BR BM cells. Twen-
ty-one days after marrow transplant, the recipients were given DLI with
33107 B10.BR spleen cells (untreated, CD4-depleted, or CD8-depleted as in
Fig. 4) from donors preimmunized with AKR alloantigens (see MATERIALS
AND METHODS). One week later (28 days post-BMT), the mice were chal-
lenged with an i.v. dose of 1000 AKR-M2 leukemia cells. Normal, nontrans-
planted AKR mice were also injected with leukemia. The survival curves were
derived from the combined results of two experiments.
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MHC class I+II- AKR acute T cell leukemia. CD8+ donor
T cells have been found to be important in the GVL effect
against two other murine acute leukemias after DLI [15].
One was an acute myeloid tumor (C1498), and the other an
acute T cell leukemia/lymphoma (EL4) [15]. Similar to the
AKR leukemia, both of these tumors are MHC class I+II-.
The lack of MHC class II expression may explain why CD8+
cells were the dominant GVL effectors in all three murine
DLI models.
Although CD8+ T cells were essential, depletion of
CD4+ donor T cells in an MHC-matched DLI model also
significantly compromised the GVL effect (Fig. 5). If the
donor T cells in this combination were primed to host
alloantigens, however, then CD4 depletion did not signifi-
cantly diminish GVL reactivity (Fig. 6). These data suggest
that CD4+ cells play an important role during the afferent
phase of the GVL reaction, most likely by providing help to
precursor CD8+ effector cells. Evidence to support this sug-
gestion comes from data in the MHC-mismatched model,
in which administration of purified CD8+ cells induced a
significantly weaker GVL response than the combination of
CD4 and CD8 cells together (Fig. 4B and C, Table 3).
CD4+ cells may also contribute to the effector phase of the
GVL response, since CD8 depletion in the experiment
shown in Fig. 6 did not completely eliminate antitumor
reactivity. These data do not rule out the possibility that the
remaining GVL reactivity was mediated by other cells such
as NK cells or a small population of contaminating CD8+
T cells that survived the complement treatment. When
MHC-mismatched chimeras were challenged with a low
dose of leukemia, purified CD4 cells were capable of induc-
ing a modest GVL effect (Fig. 4A). The GVL effect was not
observed when the DLI-treated recipients were challenged
with higher doses of leukemia (Fig. 4B and C). Thus, puri-
fied CD4+ donor cells alone were capable of inducing an
antitumor response against the AKR acute leukemia, but the
response was relatively weak.
In the MHC-matched model, DLI with unseparated
donor spleen cells primed to host alloantigens did not
induce clinically evident GVHD in the GVL experiments
shown in Fig. 6. These results are different from our previ-
ous data, in which MHC-matched recipients given DLI
with primed cells were at risk for developing chronic
GVHD [8]. We do not know the reason for these disparate
results, but we hypothesize that one or more of the follow-
ing factors may have been influential. First, since the
GVHD is chronic in nature [8], we may not have followed
the animals long enough to observe the development of
clinically evident GVHD. Second, the leukemia challenge
may have somehow had an impact on the development of
GVHD. Previous studies have shown that mice challenged
with leukemia develop less GVHD than their unchallenged
counterparts (R.L.T., unpublished observations). Last, the
AKR hosts in these experiments were conditioned for BMT
with a higher dose of TBI than was used in our previous
studies (1100 vs. 900 cGy). Shlomchik et al. [24] have pre-
sented mouse data that suggests host antigen-presenting
cells (APCs) are required for induction of GVHD. If the
higher dose of TBI used in the current experiments resulted
in decreased levels of host-type APCs at the time of DLI, it
might explain the absence of GVHD with primed DLI.
Unfortunately, we have no techniques available to investi-
gate whether there were decreased levels of host APCs in
these chimeras at the time of DLI.
Biological properties of the leukemia may have a major
impact on which T cell subsets are needed for a GVL effect
after DLI. Levels of MHC antigen expression, costimulato-
ry molecule expression, tumor-specific antigen expression,
and kinetics of tumor growth are some of the factors that
may determine the relative roles of T-subsets. It is becom-
ing clear that CD4+ cells are important for the GVL effect
against CML [5,21,22], and selective depletion of donor
CD8 cells for DLI has not compromised the antitumor
response in patients with relapsed CML [5]. This may have
to do with the fact that CML cells often express MHC class
II antigens. Which T cells are important in GVL reactions
against the acute leukemias is unknown. We have chosen the
highly aggressive AKR T cell leukemia as a model of human
acute leukemia. Since DLI has been less effective for the
treatment of acute leukemias, compared with CML, we
hope this model may be relevant for investigating ways of
enhancing the GVL effect of DLI. Based on our results
indicating that CD8+ donor T cells are critical to the GVL
effect of DLI against the AKR acute leukemia, we are focus-
ing our efforts on enhancement of the CD8-mediated GVL
effect without increasing GVH reactivity.
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